These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37361535)

  • 41. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
    Durmus U; Duran C; Ecirli S
    J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vitamin D Deficiency Is Associated With Metabolic Risk Factors in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study in Shaanxi China.
    Wang L; Lv S; Li F; Yu X; Bai E; Yang X
    Front Endocrinol (Lausanne); 2020; 11():171. PubMed ID: 32296394
    [No Abstract]   [Full Text] [Related]  

  • 43. Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS).
    Vosnakis C; Georgopoulos NA; Rousso D; Mavromatidis G; Katsikis I; Roupas ND; Mamali I; Panidis D
    Gynecol Endocrinol; 2013 Mar; 29(3):242-5. PubMed ID: 23194076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome.
    Barber TM; Vojtechova P; Franks S
    Horm Mol Biol Clin Investig; 2013 Sep; 15(3):91-103. PubMed ID: 25436736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
    Gambineri A; Vicennati V; Genghini S; Tomassoni F; Pagotto U; Pasquali R; Walker BR
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2295-302. PubMed ID: 16551740
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals.
    Becerra-Fernández A; Pérez-López G; Román MM; Martín-Lazaro JF; Lucio Pérez MJ; Asenjo Araque N; Rodríguez-Molina JM; Berrocal Sertucha MC; Aguilar Vilas MV
    Endocrinol Nutr; 2014; 61(7):351-8. PubMed ID: 24680383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients.
    Karadağ C; Yoldemir T; Gogas Yavuz D
    Gynecol Endocrinol; 2017 Mar; 33(3):234-237. PubMed ID: 27908213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis.
    Dobbie LJ; Pittam B; Zhao SS; Alam U; Hydes TJ; Barber TM; Cuthbertson DJ
    Hum Reprod; 2023 Jun; 38(6):1168-1182. PubMed ID: 37015099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat.
    Gu M; Ruan X; Li Y; Li T; Yin C; Mueck AO
    Gynecol Endocrinol; 2022 Jul; 38(7):598-602. PubMed ID: 35616272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
    Sanchez-Garrido MA; Tena-Sempere M
    Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or =14 years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome.
    Glueck CJ; Morrison JA; Wang P
    J Pediatr Endocrinol Metab; 2008 Oct; 21(10):973-84. PubMed ID: 19209619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome.
    Ujvari D; Hulchiy M; Calaby A; Nybacka Å; Byström B; Hirschberg AL
    Hum Reprod; 2014 Jul; 29(7):1526-35. PubMed ID: 24842895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
    Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
    Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.
    Cassar S; Teede HJ; Moran LJ; Joham AE; Harrison CL; Strauss BJ; Stepto NK
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):899-906. PubMed ID: 25040369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatic manifestations of women with polycystic ovary syndrome.
    Chen MJ; Ho HN
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polycystic ovary syndrome and metabolic disorders: A review of the literature.
    Ali AT; Al-Ani O; Al-Ani F; Guidozzi F
    Afr J Reprod Health; 2022 Aug; 26(8):89-99. PubMed ID: 37585035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the pro-inflammatory cytokine tumor necrosis factor-α in adolescents with polycystic ovary syndrome.
    Pawelczak M; Rosenthal J; Milla S; Liu YH; Shah B
    J Pediatr Adolesc Gynecol; 2014 Dec; 27(6):356-9. PubMed ID: 25256873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.